Parnaparin
drugOn this page
Summary
Parnaparin (CHEMBL3707207) is a phase-3 clinical-stage oligosaccharide (ATC B01AB07); indicated across 2 conditions including thrombotic disease and retinal vein occlusion.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Oligosaccharide
- ATC class: B01AB07
- Indications: 2 conditions
- Clinical trials: 1
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3707207 |
| Name | Parnaparin |
| Type | Oligosaccharide |
| Max phase | 3 |
| ATC | B01AB07 |
Also known as: Parnaparin, PARNAPARIN
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| thrombotic disease | 3 | MONDO:0000831 | HP:0004419 |
| retinal vein occlusion | 3 | MONDO:0006951 | EFO:1001157 |
Clinical trials
Total trials: 1.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00732927 | PHASE3 | TERMINATED | Parnaparin vs Aspirin in the Treatment of Retinal Vein Occlusion |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: thrombotic disease, retinal vein occlusion